BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:11 PM
 | 
Sep 06, 2012
 |  BC Extra  |  Clinical News

Celgene gains on apremilast data

Celgene Corp. (NASDAQ:CELG) gained $3.53 to $74.49 on Thursday after apremilast met the primary endpoint in each of two identical Phase III trials to treat psoriatic arthritis. Top-line data from the PALACE-2 and 3 trials showed that the oral phosphodiesterase-4 (PDE-4) inhibitor significantly improved ACR20 response rates at week 16 vs. placebo....

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >